Kala Bio (KALA) Free Cash Flow (2016 - 2026)
Kala Bio (KALA) posted Free Cash Flow of -$2.9 million for Q1 2026, up 34.16% sequentially from -$4.4 million in Q4 2025, and up 67.22% YoY from -$1.7 million in Q1 2025.
Kala Bio (KALA) Free Cash Flow (2016 - 2026) Analysis & Trends
Kala Bio has reported Free Cash Flow for 11 years, with the latest figure at -$2.9 million in Q1 2026.
- Quarterly Free Cash Flow rose 67.22% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.7 million (down 26.02% YoY) and the FY2025 annual result came in at -$31.8 million, down 7.63% from the prior year.
- Free Cash Flow grew to -$2.9 million in Q1 2026 per KALA's latest filing, from -$4.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$2.9 million in Q1 2026 and troughed at -$25.6 million in Q2 2022.
- A 5-year average of -$10.6 million and a median of -$9.3 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow jumped 79.41% in 2023, then tumbled 125.88% in 2025.
- Over 5 years, Free Cash Flow stood at -$13.8 million in 2022, then surged by 47.39% to -$7.2 million in 2023, then surged by 35.51% to -$4.7 million in 2024, then rose by 5.79% to -$4.4 million in 2025, then surged by 34.16% to -$2.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$2.9 million, -$4.4 million, and -$10.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | -2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.90 Mn |
| Mar 31, 2026 | -2.90 Mn |
| Dec 31, 2025 | -4.40 Mn |
| Dec 31, 2025 | -4.40 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Jun 30, 2025 | -16.57 Mn |
| Jun 30, 2025 | -16.57 Mn |
| Mar 31, 2025 | -8.83 Mn |
| Mar 31, 2025 | -8.83 Mn |
| Dec 31, 2024 | -4.67 Mn |
| Dec 31, 2024 | -4.67 Mn |
| Sep 30, 2024 | -4.82 Mn |
| Sep 30, 2024 | -4.82 Mn |
| Jun 30, 2024 | -9.25 Mn |
| Jun 30, 2024 | -9.25 Mn |
| Mar 31, 2024 | -10.86 Mn |
| Mar 31, 2024 | -10.86 Mn |
| Dec 31, 2023 | -7.24 Mn |
| Dec 31, 2023 | -7.24 Mn |